Assessing Prevalence Of Beta Lactamase Production From Clinical Isolates Of Hospitalized Patients And Comparison Of Antibiotic Susceptibility Patterns
Completed
- Conditions
- Infection
- Registration Number
- NCT00728624
- Lead Sponsor
- Pfizer
- Brief Summary
EGAST 2008 is a prospective, non interventional, multicentric study (approximately 2000 isolates from 15- 20 sites).
Objectives:
* Comparison of antimicrobial susceptibility using disc-diffusion method
* Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients
- Detailed Description
n/a n/a
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2039
Inclusion Criteria
Isolates (as specified in the observational plan) from hospitalised patients
Read More
Exclusion Criteria
Isolates obtained from outpatients will not be included for the study. Isolates from repeat cultures performed during in-patient follow-up that were previously recruited into the study will be excluded.
Isolates identified as commensals or contaminants will be excluded
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparison of antimicrobial susceptibility using disc-diffusion method duration of trial
- Secondary Outcome Measures
Name Time Method Assessing prevalence of beta-lactamase producing strains among clinical isolates obtained from hospital in-patients duration of trial
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇮🇳New Delhi, India